Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 14
  • Journal CiteScore: 3.77
  • Journal Impact Factor: 4.09
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • International Committee of Medical Journal Editors (ICMJE)
  • Zenodo
Share This Page


Bhuvnesh K. Sharma (Editor in Chief)

It is, indeed, a great honor to me to put forward a Welcome Message of “Archives in Cancer Research” by Heighten Science Publications Corp, UK. This is an open access, peer-reviewed journal, broadly focused on ground-breaking therapeutic interventions, pre-clinical and clinical trials which would facilitate to develop newer treatment paradigms for cancer therapy. This journal is intended to bring a lot of benefits to the eminent investigators engaged in cancer treatment. The journal comprehends current status to disseminate personalized or combinational treatment strategies foreseeing patient’s actual tumor response of most effective in the management of cancer. It is my great privilege serving as an Editor in Chief of this journal. I am confident that the editorial board of this journal will maintain a stringent methodological rigour peer reviewing process ensuring a quality and reliability of the findings of the articles and their trustworthiness before publishing in this journal. The Journal will continue endeavors to publish high quality of original articles on basic, pre-clinical, clinical cancer research, as well as precise reviews by adhering standards peer-review guidelines. My research endeavors include pre-clinical cancer research to envisage newer diagnostic / prognostics cancer markers to develop and validate companion cancer diagnostics. Explored studies on the targeted molecules, and melanoma stem cells involved in progression of cutaneous melanoma substantiating to redirect targeted therapy for an effective management of metastatic melanoma. My recent past research studies were focused on phenotypic and genotypic Variation and immune signatures in the process of carcinogenesis. I would encourage all the authors to publish their innovative contribution in “Archives in Cancer Research” for a global dissemination and also providing opportunity to the readers to make an informed decision on how or whether their clinical approaches should be transformed.